A clinical trail to study the effects of alpha blocker tamsulosin and drug combination alpha blocker tamsulosin and competitive muscarinic-receptor antagonist solifenacin in treatment with ureteral stent related lower urinary tract symptoms.
Not Applicable
Completed
- Conditions
- Health Condition 1: N22- Calculus of urinary tract in diseases classified elsewhere
- Registration Number
- CTRI/2020/04/024945
- Lead Sponsor
- ankit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Patients undergoing Double-J stenting for ureteral intervention were included in the study.
Exclusion Criteria
1-Patients who were previously diagnosed with benign prostatic hyperplasia or overactive bladder.
2-Pregnant women.
3- Psychiatric illness
4-Urinary tract infections.
5-Previous use of selective alpha-1- blocker and or antimuscarinic agent or with known history of orthostatic hypotension,allergy,hypersensitivity to one or more alpha blockers.
6-Patients under ICU management
7-Patients on dialysis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method